Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Start-Up Previews, February 2013

Executive Summary

This Month's Profile Group: Medtech Start-Ups Battle Advanced Skin Cancer With Innovative Technologies, features profiles of OncoSec, Sensus Healthcare, and Siva Therapeutics. Plus these Start-Ups Across Health Care: Avillion, CardioLogical Solutions, Fixes 4 Kids, RenovoRx, and Savant HWP.

You may also be interested in...



RenovoRx Inc.

Pancreatic cancer is currently the fourth leading cause of cancer death in the US, and it is primarily treated with systemic drugs that have limited ability to penetrate the pancreas. RenovoRx Inc. has developed an endovascular catheter that enables targeted delivery of either diagnostic or therapeutic fluids directly to the pancreas.

CardioLogical Solutions

The recently announced merger of two innovative cardiovascular device companies – VasoStitch Inc. and Emboline Inc. – under the name CardioLogical Solutions promises to create a full range of accessory devices to improve the safety and efficacy of transcatheter aortic valve replacement procedures performed by either an interventional cardiologist or a thoracic surgeon.

Siva Therapeutics Inc.

Siva Therapeutics Inc. aims to destroy skin cancer cells from within by using its SivaRods, gold nanoparticles that combine with near-infrared light to create precisely targeted hyperthermia that destroys tumors with minimal collateral damage.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV003999

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel